These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15918781)

  • 1. Hepatitis C virus infection: the new global epidemic.
    Butt AA
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):241-9. PubMed ID: 15918781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus guidelines for the management of hepatitis C infection.
    Consensus Guidelines Committee for the Management of Hepatitis C Infection
    Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of hepatitis C virus infection].
    Zeuzem S
    Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of hepatitis C: from empiricism to eradication.
    Pawlotsky JM
    Hepatology; 2006 Feb; 43(2 Suppl 1):S207-20. PubMed ID: 16447262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C and treatment with pegylated interferon and ribavirin.
    Gotto J; Dusheiko GM
    Int J Biochem Cell Biol; 2004 Oct; 36(10):1874-7. PubMed ID: 15203100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C: epidemiology, diagnosis, natural history and therapy.
    Pol S; Vallet-Pichard A; Corouge M; Mallet VO
    Contrib Nephrol; 2012; 176():1-9. PubMed ID: 22310776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapies in Hepatitis C virus. Preface.
    Pockros PJ
    Clin Liver Dis; 2009 Aug; 13(3):xiii. PubMed ID: 19628152
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy of hepatitis C].
    Moradpour D; Blum HE
    Praxis (Bern 1994); 2002 May; 91(22):977-82. PubMed ID: 12094432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
    Morishima C; Polyak SJ; Ray R; Doherty MC; Di Bisceglie AM; Malet PF; Bonkovsky HL; Sullivan DG; Gretch DR; Rothman AL; Koziel MJ; Lindsay KL;
    J Infect Dis; 2006 Apr; 193(7):931-40. PubMed ID: 16518754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hepatitis C].
    Moradpour D; Blum HE
    Ther Umsch; 2004 Aug; 61(8):493-8. PubMed ID: 15457965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon for hepatitis C patients with psychiatric disorders.
    Rifai MA; Bozorg B; Rosenstein DL
    Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
    [No Abstract]   [Full Text] [Related]  

  • 15. Update on the treatment of chronic hepatitis C in HIV-infected patients.
    Soriano V; Barreiro P; Martin-Carbonero L; Vispo E; Garcia-Samaniego J; Labarga P; Gonzalez-Lahoz J
    AIDS Rev; 2007; 9(2):99-113. PubMed ID: 17694677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
    Herrmann E; Lee JH; Marinos G; Modi M; Zeuzem S
    Hepatology; 2003 Jun; 37(6):1351-8. PubMed ID: 12774014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S
    Transplant Proc; 2005 Dec; 37(10):4403-5. PubMed ID: 16387131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C: diagnosis and treatment.
    Wilkins T; Malcolm JK; Raina D; Schade RR
    Am Fam Physician; 2010 Jun; 81(11):1351-7. PubMed ID: 20521755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Into the light: strategies for battling hepatitis C.
    Bacon BR; McHutchison JG
    Am J Manag Care; 2007 Dec; 13 Suppl 12():S319-26. PubMed ID: 18095780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic hepatitis C in southern Taiwan.
    Chuang WL; Yu ML; Dai CY; Chang WY
    Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.